PERTINENT FINDINGS: Study A26 met all primary endpoints and demonstrated that a FTP visual stratification method enables trained physician readers to differentiate between subjects with early symptomatic AD who have a quantitation-based high tau burden (AD-signature SUVr > 1.46) versus a non–high tau burden. The gene discussed is MAPT; the disease is Alzheimer disease.